KSHV vFLIP Is Essential for the Survival of Infected Lymphoma Cells

Ilaria Guasparri, Shannon A. Keller, and Ethel Cesarman

Weill Medical College of Cornell University, New York, NY 10021

Abstract

Primary effusion lymphomas (PELs) associated with infection by the Kaposi’s sarcoma–associated herpesvirus (KSHV/HHV–8) have constitutive nuclear factor (NF)–κB activity that is essential for their survival, but the source of this activity is unknown. We report that viral FADD-like interleukin-1–converting enzyme [FLICE/caspase 8]–inhibitory protein (FLIP) activates NF-κB more potently than cellular FLIP in B cells and that it is largely responsible for NF-κB activation in latently infected PEL cells. Elimination of vFLIP production in PEL cells by RNA interference results in significantly decreased NF-κB activity, down-regulation of essential NF-κB–regulated cellular prosurvival factors, induction of apoptosis, and enhanced sensitivity to external apoptotic stimuli. vFLIP is the first virally encoded gene shown to be essential for the survival of naturally infected tumor cells.

Key words: HHV-8 • NF-κB • Kaposi’s sarcoma • AIDS • viral oncogenes

Introduction

Activation of nuclear factor (NF)–κB is a mechanism used by lymphomagenic viruses to prolong cellular survival and induce proliferation. EBV and human T cell leukemia virus 1 (HTLV-1) encode viral (v) oncoproteins, mainly LMP1 and Tax, that subvert cellular signaling pathways to constitutively activate NF-κB (1–4). Another lymphomagenic virus, Kaposi’s sarcoma–associated herpesvirus (KSHV, also called human herpesvirus 8 or HHV-8), infects B cells and is present in B cell lymphoproliferative disorders, specifically primary effusion lymphomas (PELs; reference 5) and a subset of cases of multicentric Castleman’s disease (6) and associated plasmablastic lymphomas (7). Like other virus-associated lymphomas, the transcription factor NF-κB is constitutively activated in PEL cells, and is essential for their survival (8). We postulated that expression of viral genes was a primary source of constitutive activation of NF-κB in PEL cells. Consistent with this has been our previous finding that types of NF-κB complexes, although varying in levels of intensity, are identical among different KSHV-infected PEL cell lines, which suggests a common source of activation.

Apoptotic cell death is a tightly regulated process that is crucial for the defense against certain infectious diseases and cancer. Interaction between immune effector cells as well as some infected cells can lead to apoptosis by the exogenous or death receptor pathway. Death receptors are a family of transmembrane proteins that belong to the TNF family of receptors (9). They all contain a cytoplasmic sequence called death domain (DD) that couples each receptor to caspases, inducing death signals that trigger apoptosis. Current understanding suggests that binding of extracellular death ligands to their receptors, such as the Fas ligand to Fas, results in conformational changes of preformed receptor clusters (10). This leads to recruitment of the bipartite molecule Fas-associated (FA)DD, composed of an amino terminal death effector domain (DED) and a carboxyl terminal DD. FADD binds to Fas via homophilic DED–DED interactions and recruits the upstream DED-containing procaspase 8 to the receptor by homophilic DED–DED interactions. This forms the death-inducing signaling complex (DISC), which autoactivates itself via proteolytic cleavage of caspase 8 and induces apoptosis by subsequent cleavage of downstream effector caspases.

Abbreviations used in this paper: DD, death domain; DED, death effector domain; DISC, death-inducing signaling complex; Doxy, doxycycline; EMSA, electrophoretic mobility shift assay; FA, Fas-associated; FLIP, FADD-like interleukin-1–converting enzyme [FLICE/caspase 8]–inhibitory protein; HTLV-1, human T cell leukemia virus 1; IBL, immunoblastic lymphoma; IKK, IκB kinase; KSHV, Kaposi’s sarcoma–associated herpesvirus; LANA, latency-associated nuclear antigen; NF, nuclear factor; PARP, poly (ADP-ribose) polymerase; PEL, primary effusion lymphoma; si, small interfering; vCYC, viral cyclin; vGPCR, viral G protein–coupled receptor.
Apoptosis is tightly regulated and can be inhibited at the receptor level (receptor endocytosis, soluble ligands, and decoy receptors) during signal transduction and at the effector stage (caspase inhibitors such as CrmA, p35, IAPs, BCL-2, etc.). The transcription factor NF-κB can inhibit apoptosis by controlling the expression of some of these antiapoptotic inhibitory proteins. A different and direct mechanism of apoptosis inhibition is mediated by a group of antiapoptotic inhibitory proteins. A different and direct apoptosis by controlling the expression of some of these cellular FLIPs (cFLIP but murine herpesvirus 68 does not. KSHV vFLIP has two DEDs with slight homology to cFLIP. The first described and characterized, both of which can inhibit caspase 8 activation at the DISC. These are cFLIPL (long form) and cFLIPs (short form), which correspond to splice variants. cFLIPs consists of two DEDs with a short cytoplasmic tail, whereas cFLIPL has an additional COOH-terminal caspase domain and resembles procaspase 8 in its overall structural organization, but lacks proteolytic activity (12). Only cFLIPL has been found in human B cells by us (unpublished data) and others (13) when using antibodies that recognize both protein forms. Several viruses contain proteins with two DED with slight homology to cFLIP. The first described and most studied are MC159L from the Molluscum Contagiosum virus, E8 from the Equine Herpes Virus 2, and ORF71/K13 from KSHV (11, 14). Rhesus rhadinovirus and herpesvirus saimiri also contain FLIP homologues, but murine herpesvirus 68 does not. KSHV vFLIP has two DED domains, and structurally most closely resembles cFLIPs. When transfected into a murine B cell lymphoma cell line, which was subsequently injected into immunocompetent mice, it facilitated tumor growth, suggesting that in confers cells with resistance to T cell–induced apoptosis (15). KSHV vFLIP has also been shown to be able to activate the IκB kinase (IKK) complex and NF-κB in a variety of ectopic overexpression systems, and to be present in IKK complexes in PEL cells (14, 16, 17). In addition, a recent paper by An et al. showed that vFLIP is responsible for IL-6 expression in a PEL cell line, where suppression of vFLIP resulted in a 100% reduction of AP-1 transcriptional activity and 70% reduction of NF-κB activity, providing the first direct evidence indicating that vFLIP is responsible for a significant proportion of the constitutive NF-κB activity observed in PEL cells (18).

In addition to KSHV vFLIP, three different viral transmembrane proteins have been shown to induce signaling that leads to NF-κB activation in ectopic expression systems. These are K1 (19), viral G protein–coupled receptor (vGPCR; reference 20), and K15 (21). We sought to confirm previous findings suggesting that vFLIP is responsible for initiating and maintaining the signaling cascade responsible for NF-κB in latently infected lymphoma cells, and to exclude a possible contributory role for K1, vGPCR, and K15 during latent infection. Our studies show that these genes, vFLIP is largely responsible for the constitutive NF-κB activity in PEL cells. In addition, we show that KSHV vFLIP expression is essential for the survival of the infected lymphoma cells.

Materials and Methods

Cloning and Expression Vectors. To clone KSHV vFLIP, viral Cycin (vCYC), and cellular FLIPs (long and short forms), CDNA from the human PEL cell line BC3 was amplified using the following specific primers: vFLIP, 5′-GGGATGCGCACCT-TACGGGTT-3′ and 5′-GGGTATGCGCATAGTGGTG-3′; vCYC, 5′-GGGATGGCCAATGCAAAAC-3′ and 5′-ATAGCTGTCCAGAATGGCGG-3′; cFLIPL, 5′-GGGATGTCGCTGAAGTCATCCAT-3′ and 5′-TATTGTGAGGAGGATAAGTTC-3′; and cFLIPS, 5′-GGGATGGCTGCGTGAAGTCATCCAT-3′ and 5′-ACATGGAACAATTTCGAGATT-3′.

All the constructs were cloned into the eukaryotic expression vector pcDNA3.1 (Invitrogen). Correct orientation and sequence integrity was confirmed by nucleotide sequencing. vFLIP and cFLIPL were also cloned in frame with a COOH-terminal 3X-FLAG in a CMV14 vector backbone (Sigma-Aldrich). Comparable expression of transfected plasmids was confirmed by RT-PCR or immunoblot with an anti-FLAG monoclonal antibody. vFLIP was also cloned into pTRUF2-Tet (22) by blunt end ligation into the single NsiI site, and the resulting plasmid called pTRUF2-tet/vFLIP.

Cell Lines and Culture Conditions. Cell lines used were as follows: PEL cell lines were BC1, BC2, BC5 (KSHV+/EBV−), BC3, and BCBL-1 (KSHV+/EBV+). All of these were established in our laboratory from lymphomatous effusions as described previously (23, 24), except BCBL-1 (25) that was obtained from the AIDS and Cancer Specimen Bank. Burkitt lymphoma cell lines were Namalwa and BJAB, obtained from the American Type Culture Collection. An EBV-positive immunoblastic lymphoma (IBL) cell line was derived in our laboratory from an HIV-positive patient. A lymphoblastoid cell line (LCL9001) was obtained by infection of peripheral blood lymphocytes with EBV. Cells were grown in RPMI 1640 (GIBCO BRL) supplemented with 10% heat-inactivated FBS (Atlanta Biologicals) and 50 μg/ml gentamicin (Sigma-Aldrich). The human embryonal kidney 293T cell line was grown in DMEM supplemented with 10% FBS. Cells were cultured at 37°C in a humidified atmosphere with 5% CO2. NF13 was established by electroporation of Namalwa cells with 10 μg/ml doxycycline (Doxy). Three clonal populations were selected having low basal transcription and up to 100-fold inducibility with the TRE-luciferase reporter and an NF-κB luc reporter, as well as by RT-PCR and immunoblot analysis for vFLIP. One of these, NF-13, was chosen to evaluate cellular gene expression.
Electrophoretic Mobility Shift Assays (EMSA). Nuclear proteins were evaluated for binding to a 32P-labeled oligonucleotide probe corresponding to the IκB NF-binding sequence (a gift from H.-C. Liou, Weill Medical College of Cornell University) or Oct-1 (Promega) by EMSA. The methodology used was described previously in detail (8).

Northern Blot Analysis. Total RNA was extracted with the RNAZOL solution (GIBCO BRL) according to the manufacturer’s instructions. Poly(A)-selected RNA was isolated with the PolyATract mRNA Isolation System (Promega). RNA samples were treated with 2 U of RNase-free DNase I (Boehringer) before Northern blot analysis. 800 ng aliquots of poly(A)-selected RNA were separated electrophoretically in 1.5% denaturing formaldehyde agarose gel and blotted onto nylon filters (Du pont). After fixation, the blots were subjected to hybridization to PCR-generated double-stranded DNA probes that had been 32P-labeled by the random primer extension method. To evaluate K15 expression, probes for the predominant (P) and minor (M) forms were used. Washing of the filters and autoradiography was performed according to standard methodology.

Transient Transfection and Luciferase Assays. BJAB and Namalwa cells (5 x 10^6) were transfected by electroporation (Gene Pulser II; Bio-Rad Laboratories) at settings of 270 mV and 975 μF in 0.8-cm cuvettes (Invitrogen). The amount of DNA transfected was equally divided by addition of pcDNA3.1 control empty vector. All the transfections were performed in the presence of pRsv-RL vector (Promega), encoding renilla luciferase, to normalize the results for the transfection efficiencies. After 48 h, lysates were prepared using 1X cell culture lysis reagent as specified by the manufacturer (Promega). Luciferase assays were performed with a luminometer (Dynex Tech). The NF-κB reporter derived from a Igκ promoter was provided by H.-C. Liou. Each experiment was independently performed a minimum of three times, and within each experiment each transfection was performed in triplicate.

Transient transfection of vCYC was performed using FuGene 6 transfection reagent (Roche). This method is highly efficient for transfection of BC-3 cells, achieving delivery into up to 90% of cells as determined by a control green fluorescent protein– associated nuclear antigen (LANA; ABI); anti-vCYC (Exalpha); anti-cFLIP, anti–cIAP-1, and cIAP-2 (Qbiogene); anti–Bcl-X, anti–Bcl-2, and anti–IL-6 (Santa Cruz Biotechnology, Inc.); anti-Caspase 3 (Upstate Biotechnology); anti-poly (ADP-ribose) polymerase (PARP) (BD Biosciences); anti–latency-associated nuclear antigen (LANA; ABI); anti-vCYC (Exalpha); and anti–β-actin and anti-FLAG (Sigma-Aldrich).

Flow Cytometry Analysis. Cells were placed in culture at a density of 7.5 x 10^6 cells/ml without Doxy (Sigma-Aldrich) or with 2 μg/ml Doxy for 48 h. Namalwas were also evaluated with and without 2 μg/ml Doxy as a control for drug effects. BC-3 cells that were untransfected, mock-transfected, or transfected with siRNA were collected 48 h after transfection. Lysates were prepared in standard radioimmunoprecipitation assay buffer supplemented with 1 μg/ml each of aprotones, leupeptin, and pepstatin; 0.5 μM phenylmethylsulfonyl fluoride; and 1 μM each NAV04 and NaF (Sigma-Aldrich). Lysates were prepared from three independent experiments and subsequently evaluated by Western blotting. The proteins were quantitated by the Bradford method, and 80 μg whole cell extract was loaded onto 7.5–12.5% SDS-polyacrylamide gels. After electrophoresis, semi-dry transfer to a polyvinylidene difluoride membrane (Millipore) was performed. Blots were probed with primary Ab overnight at 4°C. Horseradish peroxidase–conjugated secondary Ab was added after washing and was detected by an enhanced chemiluminescence system (Amersham Biosciences).

The following primary Abs were used: anti-v-FLIP (provided by M. Collins, University College of London, London, UK; reference 26); anti-c-FLIP, anti–c-IAP-1, and c-IAP-2 (Qbiogene); anti–Bcl-X, anti–Bcl-2, and anti–IL-6 (Santa Cruz Biotechnology, Inc.); anti-Caspase 3 (Upstate Biotechnology); anti-poly (ADP-ribose) polymerase (PARP) (BD Biosciences); anti–latency-associated nuclear antigen (LANA; ABI); anti-vCYC (Exalpha); and anti–β-actin and anti-FLAG (Sigma-Aldrich).

Results

The KSHV-encoded FLIP (vFLIP) Can Activate NF-κB. We first sought to determine which of the KSHV-encoded genes that can activate NF-κB in ectopic expression systems is responsible for the constitutive NF-κB activity seen in PEL cells. We performed Northern blot analysis using probes for vGPCR, K1, K15 (not depicted), and vFLIP (Fig. 1), and compared the amount of transcripts in latently infected PEL cells (BC1, BC2, and BC3) to the level of NF-κB as measured by EMSAs in these three PEL cell lines. This analysis confirmed previous analyses (27, 28) in—
probed with a probe that recognizes vFLIP and vCYC was used, and filters were rephorbol acetate (TPA) for 48 h. BJAB cells were used as negative control.

cells were cotransfected with 5 and 10 cFLIPS expression vectors. (C) BC-3 cells were cotransfected with 5 and 10 ng/ml recombinant human TNF-α for 3 h (at which maximal activation was identified in previous time course experiments) before cell lysis (top). (B) Namalwa cells were cotransfected by electroporation with 5 μg of control reporter (pRL-CMV), and 5 and 10 μg of vFLIP, cFLIP L, or vFLIP P expression vectors. (C) BC-3 cells were cotransfected with 5 μg of control reporter plasmid, 0.5 μg of control renilla luciferase reporter plasmid (pRL-CMV), and vFLIP expression vector (vFLIP/pcDNA3.1) in the indicated amounts, or empty vector (pcDNA3.1). Total DNA content was maintained at 25 μg with empty vector. In all experiments, luciferase activities were measured 48 h after transfection, and firefly luciferase was normalized to renilla luciferase (control reporter) activity. Values shown are averages (± SEM) of one representative experiment out of three in which each transfection was performed in triplicate. As an experimental control, cells were transfected with reporter constructs and treated with 100 ng/ml recombinant human TNF-α for 3 h (at which maximal activation was identified in previous time course experiments) before cell lysis (top). (B) Namalwa cells were cotransfected with 5 μg of KSHV-encoded vFLIP. (A) vFLIP induces NF-κB transcriptional activity in human lymphoma cells. Namalwa cells were cotransfected by electroporation with 5 μg of control repressing activity in three PEL cell lines. Competition with cold NF-κB and random oligonucleotides has confirmed the specificity of this binding (not depicted). The level of NF-κB activity was in the following order: BC1>BC3>BC2. In all three PEL lines, activity was higher than in BJAB, a virus-negative lymphoma cell line. (middle) Northern blot analysis was performed on polyA-selected RNA extracted from the BC-1, -2, and -3 cell lines, as well as from BC3 after induction of lytic replication by treatment with tetradeoxynucleotide probe, demonstrating constitutive activity in three PEL cell lines. A probe that recognizes vFLIP and vCYC was used, and filters were rephorbol acetate (TPA) for 48 h. BJAB cells were used as negative control.

dicating that K1, vGPCR, and K15 are lytic genes that are not significantly expressed by latently infected PEL cells, whereas vFLIP is expressed at significant levels during latency. In addition, we found that the transcript encoding vFLIP is present in PEL cells at levels that correlate with the degree of NF-κB DNA-binding activity (Fig. 1). Because vFLIP is encoded in a bicistronic mRNA together with vCYC, the levels of vCYC also parallel those of NF-κB. However, in our hands, vCYC cannot activate NF-κB (see Fig. 5 B). The protein levels of vFLIP also paralleled those of NF-κB, as indicated by an immunoblot analysis using a monoclonal antibody to vFLIP (Fig. 1). Although this simple correlation is insufficient to draw firm conclusions, it prompted us to further investigate the role of vFLIP in PEL.

Activation of NF-κB by vFLIP was evaluated in Namalwa cells by transient transfection assay, using a pcDNA3.1/vFLIP construct and an NF-κB firefly luciferase reporter derived from the lck promoter. We chose Namalwa because this is a KSHV-negative B cell lymphoma line with relatively low endogenous NF-κB, and therefore, corresponds to the same lineage as PEL, but does not contain endogenous vFLIP. The luciferase activity was measured 48 h after transfection and it was found to be markedly increased in the cells transfected with vFLIP as compared with the control cells transfected with NF-κB firefly luciferase reporter and empty vector (Fig. 2 A). This is the first demonstration that vFLIP can indeed activate NF-κB in human B cells. Notably, vFLIP was a more potent activator of NF-κB than saturating doses of TNFα. Cellular FLIP (the short and long isoforms, cFLIP S and cFLIP L) were also evaluated for comparison. These were cloned.

Figure 1. Correlation of NF-κB activity and vFLIP expression in PEL cell lines. (top) EMSA using a NF-κB–specific oligonucleotide probe, demonstrating constitutive activity in three PEL cell lines. Competition with cold NF-κB and random oligonucleotides has confirmed the specificity of this binding (not depicted). The level of NF-κB activity was in the following order: BC1>BC3>BC2. In all three PEL lines, activity was higher than in BJAB, a virus-negative lymphoma cell line. (middle) Northern blot analysis was performed on polyA-selected RNA extracted from the BC-1, -2, and -3 cell lines, as well as from BC3 after induction of lytic replication by treatment with tetradeoxynucleotide probe, demonstrating constitutive activity in three PEL cell lines. A probe that recognizes vFLIP and vCYC was used, and filters were rephorbol acetate (TPA) for 48 h. BJAB cells were used as negative control.

dicating that K1, vGPCR, and K15 are lytic genes that are not significantly expressed by latently infected PEL cells, whereas vFLIP is expressed at significant levels during latency. In addition, we found that the transcript encoding vFLIP is present in PEL cells at levels that correlate with the degree of NF-κB DNA-binding activity (Fig. 1). Because vFLIP is encoded in a bicistronic mRNA together with vCYC, the levels of vCYC also parallel those of NF-κB. However, in our hands, vCYC cannot activate NF-κB (see Fig. 5 B). The protein levels of vFLIP also paralleled those of NF-κB, as indicated by an immunoblot analysis using a monoclonal antibody to vFLIP (Fig. 1). Although this simple correlation is insufficient to draw firm conclusions, it prompted us to further investigate the role of vFLIP in PEL.

Activation of NF-κB by vFLIP was evaluated in Namalwa cells by transient transfection assay, using a pcDNA3.1/vFLIP construct and an NF-κB firefly luciferase reporter derived from the lck promoter. We chose Namalwa because this is a KSHV-negative B cell lymphoma line with relatively low endogenous NF-κB, and therefore, corresponds to the same lineage as PEL, but does not contain endogenous vFLIP. The luciferase activity was measured 48 h after transfection and it was found to be markedly increased in the cells transfected with vFLIP as compared with the control cells transfected with NF-κB firefly luciferase reporter and empty vector (Fig. 2 A). This is the first demonstration that vFLIP can indeed activate NF-κB in human B cells. Notably, vFLIP was a more potent activator of NF-κB than saturating doses of TNFα. Cellular FLIP (the short and long isoforms, cFLIP S and cFLIP L) were also evaluated for comparison. These were cloned.

Figure 2. Activation of NF-κB by KSHV-encoded vFLIP. (A) vFLIP induces NF-κB transcriptional activity in human lymphoma cells. Namalwa cells were cotransfected by electroporation with 5 μg of control renilla luciferase reporter plasmid, 0.5 μg of control renilla luciferase reporter plasmid (pRL-CMV), and vFLIP expression vector (vFLIP/pcDNA3.1) in the indicated amounts, or empty vector (pcDNA3.1). Total DNA content was maintained at 25 μg with empty vector. In all experiments, luciferase activities were measured 48 h after transfection, and firefly luciferase was normalized to renilla luciferase (control reporter) activity. Values shown are averages (± SEM) of one representative experiment out of three in which each transfection was performed in triplicate. As an experimental control, cells were transfected with reporter constructs and treated with 100 ng/ml recombinant human TNF-α for 3 h (at which maximal activation was identified in previous time course experiments) before cell lysis (top). (B) Namalwa cells were cotransfected with 5 μg of control reporter (pRL-CMV), and 5 and 10 μg of vFLIP, cFLIP L, or cFLIP P expression vectors. (C) BC-3 cells were cotransfected with 5 μg of control reporter plasmid, 0.5 μg of control renilla luciferase reporter plasmid (pRL-CMV), and 5 and 10 μg of 3X-FLAG-tagged vFLIP and cFLIP P, or empty vector (p3X-FLAG-CMV14). NF-κB activation was measured using a luciferase reporter assay. No significant difference was found between FLAG-tagged and untagged proteins (not depicted). (D) Immunoblot analysis of extracts from transfected BC-3 cells using an anti-FLAG monoclonal antibody is shown (top), indicating lower protein levels for vFLIP than cFLIP L, in spite of higher NF-κB–inducing activity. Because the sizes of vFLIP and cFLIP L are very different, the bands in this figure were cut from a single gel to show only the specific band.
into the same vector (pcDNA3.1) and transiently cotransfected in Namalwa cells with the NF-κB luciferase reporter. vFLIP was a more potent activator of NF-κB than both forms of cFLIP (Fig. 2 B). When tested in 293T cells, vFLIP was also a more potent activator of NF-κB than TNFα, and the ability of vFLIP to induce NF-κB was at least 2-fold higher as compared with cFLIP L and 10-fold higher than cFLIP S (unpublished data). To assess the levels of the different FLIP proteins in the transfected cells using a single antibody, and to determine whether the differences in NF-κB activity may be explained by variability protein levels, we subcloned vFLIP and cFLIP into a vector in frame with a COOH-terminal 3X-FLAG. This also allowed us to examine the ability of these proteins to activate NF-κB when transfected into BC-3 cells and to distinguish them from the endogenous proteins. No significant differences in activity were found between FLAG-tagged and untagged proteins (unpublished data). The vFLIP-FLAG also showed higher activation of NF-κB than cFLIP-FLAG in BC-3 (Fig. 2 C) and 293T cells (not depicted). Proteins were extracted from these transfected cells, and immunoblot analysis using an anti-FLAG antibody was performed. We consistently found in BC-3 and 293T cells that the levels of cFLIP L were approximately threefold higher than those of vFLIP. This is probably due to higher translation efficiency or stability of the cFLIP L protein because these differences were not seen by RT-PCR. These results show that vFLIP has an intrinsically higher signaling capacity than cFLIP L, and that the difference between viral and cellular proteins is larger than that apparent in the reporter assays when protein levels are taken into account.

**KSHV vFLIP Induces the Expression of Cellular Antiapoptotic Genes.** To better characterize the effect of KSHV vFLIP in neoplastic B cells, this gene was cloned in pTruf2-Tet, an inducible plasmid expression vector developed in our laboratory based on a combination of the tetracycline-inducible system and adeno-associated virus (22) and was stably transfected in Namalwa cells. Selected and subcloned populations were tested for expression and inducibility of vFLIP after treatment with Doxy. Three clonal populations were selected, having low basal transcription and up to 100-fold inducibility. Results from a representative clone, designated NF13, are shown in Fig. 3. NF-κB activity was increased greater than two-fold in induced cells as compared with the uninduced control cells. Because NF-κB is a transcription factor that controls a number of cellular genes that are critical mediators of cell survival and proliferation, we evaluated the effect of vFLIP on cellular gene expression. We have identified a set of cellular genes that are antiapoptotic NF-κB targets in PEL cells. These include cFLIP L (no cFLIP short was identified in PEL cells), cIAP-1, and cIAP-2. We have also found that BCL-X L and BCL-2 are not NF-κB targets in PEL cells (unpublished data). Expression of vFLIP induced by Doxy in NF13 cells resulted in expression of cFLIP L, cIAP-1, and cIAP-2, but no changes in BCL-X L (Fig. 3). No changes in NF-κB activity or expression of cFLIP L were seen when the parental Namalwa cells were treated with Doxy. These data suggest that virus-encoded vFLIP could inhibit apoptosis by inducing expression of a specific set of cellular NF-κB–dependent antiapoptotic genes.

**Inhibition of KSHV vFLIP by RNA Interference.** We evaluated the role of vFLIP in PEL cells, which are naturally infected with KSHV and presumably a target of transformation by this virus, using RNA interference. We developed and tested a siRNA duplex that specifically targets the KSHV vFLIP sequence, but not cFLIP or any other known genomic sequence. This siRNA was transfected into a PEL cell line (BC-3) and a significant inhibition of vFLIP protein was obtained, as assessed by immunoblot analysis (Fig. 4 A). Although all experiments showed marked silencing by immunoblot analysis, it appears to be complete in some, partial in others, and seen by longer gel exposure. This is probably due to a threshold of detection by the antibody to vFLIP, where a small amount of residual vFLIP protein can no longer be detected. siRNA to vFLIP and cFLIP. Actin reprobing was performed to assure even protein loading. Doxy induction and analysis of protein expression was confirmed in three independent experiments of which one representative is shown.
vFLIP was able to inhibit basal NF-κB activity by ~80% in BC-3 cells, indicating that a substantial proportion of the constitutive NF-κB activity is being induced by vFLIP (Fig. 4 B). Scramble siRNA used as a negative control did not have a significant effect on NF-κB activity and did not affect the levels of vFLIP protein. This result confirms a previously published work in which siRNA to vFLIP was found to significantly inhibit NF-κB reporter activity in the BCBL-1 PEL cell line (18). We also confirmed that siRNA to vFLIP inhibits transcription for an AP-1 reporter construct, as demonstrated previously (reference 18 and unpublished data).

To confirm the effect of vFLIP siRNA on NF-κB activity, we performed EMSAs. We evaluated BC-1 and BC-3 cells transfected with vFLIP siRNA (or scramble siRNA) and compared with mock-transfected cells (−). Nuclear extracts were made 48 h after transfection. Silencing of vFLIP resulted in a marked decrease of NF-κB DNA binding activity (Fig. 4 C). In contrast, no significant changes were seen in the level of proteins binding to an oligonucleotide containing an octamer (Oct) motif, indicating that not all transcription factors are affected by vFLIP down-regulation.
vFLIP is encoded in a bicistronic transcript also encoding for vCYC. In addition, vFLIP is also present in a tricistronic transcript encoding the LANA and also containing downstream vCYC and vFLIP sequences. Therefore, it was important to determine whether protein production of LANA and/or vCYC is affected by the siRNA to vFLIP. Our results indicate that LANA is unaffected by siRNA to vFLIP. The reason for this protection is unclear; LANA remains unchanged even after 8 d of siRNA treatment, so it is unlikely to be due to a longer half life of the protein. In contrast, expression of vCYC is dramatically reduced (Fig. 5 A). To overcome the down-regulation of vCYC, and to be able to dissociate the effects resulting from loss of vFLIP from those due to vCYC inhibition, we transfected vCYC as a monocistronic transcript and expressed it independently of vFLIP in BC-3 cells. We were able to achieve continuous expression of vCYC at levels comparable to those of untreated BC-3 cells (Fig. 5 A). The functional effects of treatment with siRNA to vFLIP described in the next paragraphs were also seen in vCYC-transfected BC-3 cells, where vCYC protein levels were maintained in the presence of siRNA to vFLIP, and thus can be attributed to vFLIP down-regulation. In addition, transfection of vCYC did not induce NF-κB, and did not affect the NF-κB activity induced by vFLIP (Fig. 5 B); thus, we did not find vCYC to be a contributing factor to NF-κB activation.

We assumed that a single transfection of siRNA into PEL cells would lead to incomplete and transient delivery, so we modified this approach by transfecting BC-3 cells every 2 d with siRNA, thus achieving sufficient and prolonged inhibition of vFLIP in PEL cells. Proteins were extracted at various time points during the course of this experiment, and the effect of vFLIP reduction on selected cellular proteins was evaluated. siRNA to vFLIP decreased the expression of the three NF-κB-dependent cellular antiapoptotic proteins examined, cFLIP, cIAP-1, and cIAP-2 (Fig. 6), although down-regulation of cIAP-1 was not immediate, perhaps due to a long half life of this protein. Reconstitution of vCYC did not affect this down-regulation of cellular proteins, as shown for cFLIP in Fig. 5 A. siRNA to vFLIP also decreased expression of cellular IL-6, another NF-κB-dependent factor, consistent with recently published findings (18). siRNA to vFLIP did not affect the levels of cellular BCL-2 and BCL-XL proteins, which are not dependent on NF-κB in PEL cells (unpublished data), indicative of pathway specificity. These results show that vFLIP is largely responsible for sustaining the expression of cellular NF-κB–dependent antiapoptotic genes in PEL cells.
Elimination of KSHV vFLIP Leads to Apoptosis of PEL Cells. If NF-κB activity is essential for the survival of PEL cells, and vFLIP is responsible for this activity in latently infected cells, elimination of vFLIP should lead to apoptosis. However, it has never been shown that elimination of a single viral gene results in apoptosis of infected lymphoma cells. To test this, we have measured apoptosis by flow cytometry for annexin V after inhibition of vFLIP by RNA interference. Initially, we evaluated BC-3 cells transfected with siRNA for apoptosis up to 48 h after transfection. Because no significant cell death was seen, vFLIP BC-3 cells were transfected every 2 d (days 0, 2, 4, and 6), and annexin V was evaluated at 2-d intervals (days 2, 4, 6, and 8, before the next transfection), for a total of four transfactions and an 8-d time course. The number of apoptotic cells increases over time when transfected with siRNA to vFLIP, and by day 8, a significant proportion of cells (∼80%) express surface annexin V. In contrast, cells similarly transfected with nonspecific (scramble) siRNA and mock–transfected cells remain largely viable (Fig. 7 A, 18 and 13% apoptotic cells). Reconstitution of BC-3 cells with vCYC did not protect cells from apoptosis, indicating that apoptosis results from vFLIP and not vCYC suppression. siRNA to vFLIP also resulted in partial cleavage of caspase 3 and PARP, confirming induction of apoptosis (Fig. 7 B). Because the possibility remained that multiple transfections were inducing stress and sensitizing the cell to apoptosis in the context of NF-κB inhibition, we determined whether apoptosis would also occur in cells that had only been transfected once (at day 0), or twice (at days 0 and 4). A similar proportion of cells underwent apoptosis as in cells transfected four times (Fig. 7 A), but in all experiments it took 6–8 d for this process to be obvious.

To exclude the possibility that the vFLIP siRNA induces apoptosis through toxicity or other nonspecific mechanisms mimicking those seen upon inhibition of NF-κB, we tested additional cell lines. siRNA was transfected every 2 d for 8 d into four additional PEL cell lines, containing KSHV and expressing vFLIP (BC-1, BCBL-1, BC-2, and BC-5), and into four cell lines lacking KSHV, which included two Burkitt lymphoma cell lines with low constitutive NF-κB activity (BJAB and Namalwa), as well as one EBV-positive immunoblastic lymphoma cell line established in our laboratory (IBL) and one lymphoblastoid cell line (LCL9001), both with high constitutive NF-κB activity. The results shown in Fig. 8 clearly demonstrate that transfection of siRNA to vFLIP only leads to apoptosis of the PEL cell lines, whereas the cell lines lacking endogenous vFLIP are not significantly affected by this treatment.

vFLIP has been shown to inhibit apoptosis by virtue of containing two DEDs, and preventing signaling from death receptors to the upstream caspases (29, 30). vFLIP has also been shown to inhibit Fas-mediated apoptosis and caspase activation when transfected into a cell line that is sensitive to death induction by this pathway (15). We evaluated whether vFLIP contributes to resistance to Fas-mediated apoptosis in PEL cells. We chose the sixth day time point that provides suboptimal apoptosis by vFLIP inhibition alone. We found that BC-3 cells are largely resistant to Fas-mediated apoptosis, but when treated with siRNA to vFLIP, there was a further increase in annexin V positivity when Fas was engaged by agonistic antibodies (Fig. 9). This increase was statistically significant (P = 0.001). Therefore, reduction of vFLIP not only leads to spontaneous apoptosis but it sensitizes PEL to extrinsic apoptotic stimuli.
Discussion

Classic approaches to determine which proteins of onco-
genic viruses are involved in transformation cannot be used
to characterize KSHV. Although this virus is associated
with specific lymphoma subtypes (suggesting a role in their
pathogenesis), it is clearly not sufficient for their develop-
ment and additional cofactors are necessary. One of these
is probably EBV because a large proportion of PEL cells are
coinfected by both viruses, but other cofactors are still un-
known. A puzzling observation has been that in spite of the
fact that KSHV encodes several genes that are transforming
in vitro and/or are homologous to cellular oncogenes, in
vivo infection of B cells does not transform them (31).
This clearly distinguishes KSHV from EBV and may ex-
plain why KSHV-associated lymphomas are much less
common than those associated with EBV infection. Never-
theless, once a lymphoma develops, when both KSHV and
EBV are present, KSHV expresses a set of latent genes,
whereas EBV latent gene expression is fairly restricted (32).
In addition, alterations in common oncogenes and tumor
suppressor genes are rare, in spite of multiple cytogenetic
abnormalities (33, 34). These observations suggest that
KSHV may be a sustaining force in PEL, and the results
presented here support this notion.

We propose a model, illustrated in Fig. 10, whereby
vFLIP may act by two mechanisms: (a) by preventing acti-
vation of the DISC complex, and (b) by activating the NF-
κB signaling pathway, therefore inducing survival signals.
The potential for vFLIP to directly inhibit DISC function
is mainly suggested by homology to cFLIP long and short
forms, which have been clearly shown to affect cleavage
and/or release of caspase 8 (29, 30). However, there are
minimal data to support a direct role of vFLIP in the DISC;
a single paper indicates that vFLIP has the potential of play-
ing such a role because it can bind and inhibit cleavage of
procaspase 8 (35), but this interaction has only been shown
in transfected HeLa cells and never documented in PEL
cells. The second pathway, whereby vFLIP induces NF-κB
and inhibits apoptosis by inducing expression of cellular
prosurvival factors is clearly demonstrated by our data. We
suggest that vFLIP forms an active signaling complex,
which we propose to call a life-inducing signaling complex
(LISC). At this time, it is unknown what elements are in
this complex in naturally KSHV-infected B cells, and
whether activity depends on the presence and/or activation
of TNF receptors. PEL cells do not express many of the
members of the TNF receptor family, and lack CD40,
which is expressed in most other B cell types and tumors.
However, they do express low levels or TNF-R2 and vari-
able levels of Fas (CD95; unpublished data) and TRAIL re-
cptors (36). Published work based on ectopic overexpres-
sion systems and PEL cell lines suggests that vFLIP can
associate with the IKK complex, NIK, RIP, and TRAFs,
suggesting that these are components of the life-inducing
signaling complex (14, 16, 17). PEL cells express abundant
TRAF-2 protein, and variable levels of other TRAFs, but
no TRAF-1 (unpublished data). Binding of TRAF-2 to
the complex containing vFLIP probably leads to activation
of a kinase, perhaps RIP, MEKK1, or another as yet unde-
defined kinase that in turn leads to phosphorylation and acti-
vation of JNK (18) and the IKK complex. In turn, this
would lead to IkBα phosphorylation and degradation,
followed by release of NF-κB, that in PEL cells is formed
mainly by p65(Rel-A)/p50 heterodimers. Transcriptional
activation of cellular prosurvival proteins, including cIAP-1,
cIAP-2, and vFLIP, as well as cytokines such as IL-6, leads
to protection of virally infected cells from spontaneous
apoptosis. Of note, cFLIP feeds back into the same path-
way by interfering with the function of the DISC. Our
data indicating that vFLIP protects PEL cells from FAS-
mediated apoptosis can be explained by direct interference
of caspase activation by vFLIP, or by an indirect effect me-
diated by cFLIP and cIAP up-regulation.

In these studies, apoptosis was not immediate upon
down-regulation of vFLIP, and significant apoptosis was
only seen after 6 d of treatment with siRNA to vFLIP,
whether these were transfected once, twice, or four times.
A possible explanation is that some of the antiapoptotic
proteins that are controlled by NF-κB have relatively long
half lives, and their decrease is gradual upon vFLIP silenc-
ing, as seen in the case of cIAP-1. It is likely that a thresh-
old exists in which a combination of antiapoptotic factors
are no longer sufficient to protect the cells from apoptotic
stimuli. For example, BCL-2 and BCL-Xl are present
throughout the time course of our experiment, and they
may play a protective role until down-regulation of other
factors reaches a critically low level. In addition, we have
examined expression of a set of antiapoptotic proteins that
we identified in previous analysis as being NF-κB–dependent (unpublished data), but it is likely that additional factors play a role in this process. It is also possible that silencing of vFLIP does not truly induce spontaneous apoptosis, but rather sensitizes cells to extrinsic apoptotic stimuli, including stress and low levels of basal death receptor signaling. Therefore, it is very likely that down-regulation of vFLIP will also sensitize cells to cytotoxic compounds and greatly enhance their therapeutic effect.

Our data support the theory that vFLIP, out of all KSHV-encoded genes, is the gene most functionally analogous to that of EBV-encoded oncoproteins LMP-1 and HTLV-I–encoded Tax. Although obvious functional differences exist between these three proteins, they share expression during latency and the ability to activate NF-κB. Activation of NF-κB has emerged as a method by which EBV, HTLV-1, and KSHV protect the host cell from apoptosis to ensure establishment of viral latency and stable infection, with the unfortunate result of becoming a common pathway in viral lymphomagenesis.

Suppression of vFLIP induces apoptosis of PEL cells, demonstrating that this single gene encoded by KSHV is essential for the survival of infected lymphoma cells. This is the first demonstration that elimination of a single viral protein leads to the death of infected lymphoma cells. Our findings identify vFLIP as a disease-specific therapeutic target for the treatment of PEL and perhaps other KSHV-associated diseases.

This work was supported by National Institutes of Health grant CA68939 and a Leukemia and Lymphoma Society Translational Research grant (to E. Cesarman).

Submitted: 27 August 2003
Accepted: 2 March 2003

References
1. Suzuki, T., H. Hirai, J. Fujisawa, T. Fujita, and M. Yoshida. 1993. A transactivator Tax of human T-cell leukemia virus type I binds to NF-κB p50 and serum response factor (SRF) and associates with enhancer DNAs of the NF-κB site and CarG box. *Onco. gen. 8:2391–2397.
2. Yin, M.J., L.B. Christerson, Y. Yamamoto, Y.T. Kwak, S. Xu, F. Mercurio, M. Barbosa, M.H. Cobb, and R.B. Gaynor. 1998. HTLV-I Tax protein binds to MEKK1 to stimulate IkappaB kinase activity and NF-kappaB activation. *Cell. 93:875–884.
3. Laherty, C., H. Hu, O. Opipari, F. Wang, and V. Dixit. 1992. The Epstein-Barr virus LMP-1 gene product induces A20 zinc finger protein expression by activating nuclear factor κB. *J. Biol. Chem. 267:24157–24160.
4. Kilger, E., A. Kieser, M. Baumann, and W. Hammerschmidt. 1998. Epstein-Barr virus–mediated B–cell proliferation is dependent upon latent membrane protein 1, which stimulates an activated CD40 receptor. *EMBO J. 17:1700–1709.
5. Cesarman, E., Y. Chang, P.S. Moore, J.W. Said, and D.M. Knowles. 1995. Kaposi's sarcoma–associated herpesvirus–like DNA sequences in AIDS–related body cavity–based lymphomas. *N. Engl. J. Med. 332:1186–1191.
6. Gessain, A., A. Sudaka, J. Brière, N. Fouchard, M.-A. Nicola, B. Rio, M. Arborio, X. Troussard, J. Aussuin, J. Diebold, and G. de Thé. 1995. Kaposi sarcoma–associated herpes–like virus (Human Herpesvirus Type 8) DNA sequences in multicentric Castleman's disease: Is there any relevant association in non–human immunodeficiency virus–infected patients? (Letter to the Editor). *Blood. 87:414–416.
7. Dupin, N., T.L. Diss, P. Kellam, M. Tulliez, M.Q. Du, D. Sicard, R.A. Weiss, P.G. Isaacsen, and C. Boshoff. 2000. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8–positive plasmablastic lymphoma. *Blood. 95:1406–1412.
8. Keller, S.A., E.J. Schattner, and E. Cesarman. 2000. Inhibition of NF-κB induces apoptosis of KSHV–infected primary effusion lymphoma cells. *Blood. 96:2537–2542.
9. Strasser, A., L. O'Connor, and V.M. Dixit. 2000. Apoptosis signaling. *Annu. Rev. Biochem. 69:217–245.
10. Siegel, R.M., J.K. Frederiksen, D.A. Zacharias, M. Johnson, D. Lynch, R.Y. Tsien, and M.J. Lenardo. 2000. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. *Science. 288:2354–2357.
11. Thome, M., P. Schneider, K. Hofmann, H. Fickenscher, E. Meinl, F. Neipel, C. Mattmann, K. Burns, J.L. Bodmer, M. Schroter, et al. 1997. Viral FLICE–inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. *Nature. 386:517–521.
12. French, L.E., and J. Tschopp. 2002. Defective death receptor signaling as a cause of tumor immune escape. *Semin. Cancer Biol. 12:51–55.
13. Hennino, A., M. Berard, P.H. Kramer, and T. Defrance. 2001. FLICE–inhibitory protein is a key regulator of germline center B cell apoptosis. *J. Exp. Med. 193:447–458.
14. Chaudhary, P.M., A. Jasmin, M.T. Eby, and L. Hood. 1999. Modulation of the NF–kappa B pathway by virally encoded death effector domains–containing proteins. *Oncogene. 14: 5738–5746.
15. Djerbi, M., V. Screpanti, A.I. Catrina, B. Bogen, P. Bieberfeld, and A. Grandien. 1999. The inhibitor of death receptor signaling, FLICE–inhibitory protein defines a new class of tumor progression factors. *J. Exp. Med. 190:1025–1032.
16. Liu, L., M.T. Eby, N. Rathore, S.K. Sinha, A. Kumar, and P.M. Chaudhary. 2002. The human herpes virus 8–encoded viral FLICE inhibitory protein physically associates with and persistently activates the IkappaB kinase complex. *J. Biol. Chem. 277:13745–13751.
17. Field, N., W. Low, M. Daniels, S. Howell, L. Daviet, C. Boshoff, and M. Collins. 2003. KSHV vFLIP binds to IKK–gamma to activate IKK. *J. Cell Sci. 116:3721–3728.
18. An, J., Y. Sun, R. Sun, and M.B. Rettig. 2003. Kaposi’s sarcoma–associated herpesvirus encoded vFLIP induces cellular IL–6 expression: the role of the NF–kappaB and JNK/AP1 pathways. *Onco. gen. 22:3371–3385.
19. Samaniego, F., S. Pati, J.E. Karp, O. Prakash, and D. Bose. 2000. Human Herpesvirus 8 K1–associated nuclear factor–kappa B–dependent promoter activity: role in Kaposi’s sarcoma inflammation? *J. Natl. Cancer Inst. Monogr. 2000:15–23.
20. Patti, S., M. Cavrois, H.G. Guo, J.S. Foulke, Jr., J. Kim, R.A. Feldman, and M. Reitz. 2001. Activation of NF–kappaB by the human herpesvirus 8 chemokine receptor ORF74: evidence for a paracrine model of Kaposi’s sarcoma pathogenesis. *J. Virol. 75:8660–8673.
21. Jenner, R.G., and C. Boshoff. 2002. The molecular pathology of Kaposi’s sarcoma–associated herpesvirus. *Biochim. Bio-
22. Cannon, M., N.J. Philpott, and E. Cesarman. 2003. The Kaposi’s sarcoma-associated herpesvirus G protein-coupled receptor has broad signaling effects in primary effusion lymphoma cells. J. Virol. 77:57–67.

23. Cesarman, E., P.S. Moore, P. Rao, G. Inghirami, D.M. Knowles, and Y. Chang. 1995. In vitro establishment and characterization of two acquired immunodeficiency syndrome-related lymphoma cell lines (BC-1 and BC-2) containing Kaposi’s sarcoma-associated herpesvirus-like (KSHV) DNA sequences. Blood. 86:2708–2714.

24. Arvanitakis, L., E.A. Mesri, R. Nador, J.W. Said, A.S. Asch, D.M. Knowles, and E. Cesarman. 1996. Establishment and characterization of a primary effusion (body cavity-based) lymphoma cell line (BC-3) harboring Kaposi’s sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus. Blood. 88:2648–2654.

25. Renne, R., W. Zhong, B. Herndier, M. McGrath, N. Abbe, D. Kedes, and D. Ganem. 1996. Lytic growth of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nat. Med. 2:342–346.

26. Low, W., M. Harries, H. Ye, M.Q. Du, C. Boshoff, and M. Collins. 2001. Internal ribosome entry site regulates translation of Kaposi’s sarcoma-associated herpesvirus FLICE inhibitory protein. J. Virol. 75:2938–2945.

27. Sarid, R., O. Flore, R.A. Bohenzky, Y. Chang, and P.S. Moore. 1998. Transcription mapping of the Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) genome in a body cavity-based lymphoma cell line (BC-1). J. Virol. 72:1005–1012.

28. Sun, R., S.F. Lin, K. Staskus, L. Gradoville, E. Grogan, A. Haase, and G. Miller. 1999. Kinetics of Kaposi’s sarcoma-associated herpesvirus gene expression. J. Virol. 73:2232–2242.

29. Krueger, A., I. Schmitz, S. Baumann, P.H. Krammer, and S. Kirchhoff. 2001. Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. J. Biol. Chem. 276:20633–20640.

30. Micheau, O., M. Thome, P. Schneider, N. Holler, J. Tschopp, D.W. Nicholson, C. Briand, and M.G. Grutter. 2002. The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex. J. Biol. Chem. 277:45162–45171.

31. Mesri, E.A., E. Cesarman, L. Arvanitakis, S. Rafii, M.A.S. Moore, D.M. Knowles, and A.S. Asch. 1996. Human herpesvirus-8/Kaposi’s sarcoma-associated herpesvirus is a new transmissible virus that infects B cells. J. Exp. Med. 183:2385–2390.

32. Horenstein, M.G., R.G. Nador, A. Chadburn, E.M. Hyjek, G. Inghirami, D.M. Knowles, and E. Cesarman. 1997. Epstein-Barr virus latent gene expression in primary effusion lymphomas containing Kaposi’s sarcoma-associated herpesvirus human herpesvirus-8. Blood. 90:1186–1191.

33. Nador, R.G., E. Cesarman, A. Chadburn, D.B. Dawson, M.Q. Ansari, J. Said, and D.M. Knowles. 1996. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi’s sarcoma-associated herpesvirus. Blood. 88:645–656.

34. Drexler, H.G., C.C. Uphoff, G. Gaidano, and A. Carbone. 1998. Lymphoma cell lines: in vitro models for the study of HHV-8+ primary effusion lymphomas (body cavity-based lymphomas). Leukemia. 12:1507–1517.

35. Belanger, C., A. Gravel, A. Tomoii, M.E. Janelle, J. Gosselin, M.J. Tremblay, and L. Flamand. 2001. Human herpesvirus 8 viral FLICE-inhibitory protein inhibits Fas-mediated apoptosis through binding and prevention of procaspase-8 maturation. J. Hum. Virol. 4:62–73.

36. Toomey, N.L., V.V. Deyev, C. Wood, L.H. Boise, D. Scott, L.H. Liu, L. Cabral, E.R. Podack, G.N. Barber, and W.J. Harrington, Jr. 2001. Induction of a TRAIL-mediated suicide program by interferon alpha in primary effusion lymphoma. Oncogene. 20:7029–7040.
The authors regret that an incorrect gel image was shown in Fig. 4 A. The correct data are shown below.

Figure 4. Inhibition of endogenous vFLIP by siRNA results in depletion of constitutive NF-κB activity in PEL cells. (A) BC-3 cells were transfected with a vFLIP siRNA (v) and scramble siRNA (s) and compared with mock-transfected cells (–). Protein extracts were prepared 48 h after transfection. Actin reprobing was performed to assure even protein loading. This experiment has been performed at least 10 times, and a representative immunoblot is shown. (B) BC-3 cells were transfected with an NF-κB luciferase reporter plasmid and either scramble siRNA as a control or siRNA for vFLIP. Luciferase assays were performed 48 h after transfection. Values shown are averages (± SEM) of one representative experiment out of three in which each transfection was performed in triplicate. (C) Electrophoretic mobility shift assays using a radiolabeled probe containing an NF-κB–binding site. BC-1 and BC-3 cells were transfected with vFLIP siRNA (v) or scramble siRNA (s) and compared with mock-transfected cells (–). Cold competition using 50-fold molar excess of an unlabeled NF-κB oligonucleotide (c) demonstrated the specificity of the protein–DNA-binding complexes. Nuclear extracts were prepared 48 h after transfection. In the lane labeled H2O, water was used instead of nuclear extract. Binding to a radiolabeled oligonucleotide containing an octamer (Oct) motif was similarly examined as a control for specificity and for nuclear protein amount (bottom), where cold competition (c) was performed with nuclear extracts from mock-transfected cells and excess unlabeled oligonucleotide containing an octamer motif. This experiment was performed three times with similar results.